Average Insider

Where insiders trade, we follow

$ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Sanjeev Luther
CEO
6
Employees
$0.28
Current Price
$2.81M
Market Cap
52W Low$0.26
Current$0.280.5% above low, 99.5% below high
52W High$4.05

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys11$2,000,000.004,000,000All Buys
Sells00--
3 monthsBuys11$2,000,000.004,000,000All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Feb 10, 2026
Cherington Charles
10% Owner
Purchase4,000,000$0.50$2,000,000.00View Details
2 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Mar 24, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
May 5, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Mar 11, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.29